Ttsiya Wart Remover

Description

No relevant information is available for SPL code 34089-3.

Uses and Indications

This drug is indicated for the removal of warts. The recommended directions for use involve washing the affected area, soaking the wart in warm water for 5 minutes, thoroughly drying the area, and applying one drop at a time to ensure complete coverage of each wart. The application should be allowed to dry and may be repeated once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed thoroughly, and warts may be soaked in warm water for up to 5 minutes to facilitate treatment. After soaking, the area must be dried completely.

The medication should be applied by gently squeezing the tube to dispense one drop at a time, ensuring that each wart is sufficiently covered. It is important to allow the application to dry completely.

This procedure may be repeated once or twice daily as needed, continuing until the wart is removed, for a maximum duration of 12 weeks.

Contraindications

Use of this product is contraindicated in individuals with diabetes or poor blood circulation due to the potential for compromised healing and increased risk of adverse effects.

Application is not recommended on irritated skin or any areas that are infected or reddened, as this may exacerbate the condition. Additionally, the product should not be applied to moles, birthmarks, warts with hair, genital warts, or warts located on the face or mucous membranes to prevent potential complications and irritation.

Warnings and Precautions

For external use only, this product is flammable and should be kept away from fire and flames. It is imperative that the product not be applied to irritated skin or any areas that are infected or reddened. Additionally, use is contraindicated on moles, birthmarks, warts with hair, genital warts, or warts located on the face or mucous membranes. The product is not recommended for individuals with diabetes or those who have poor blood circulation.

Healthcare professionals should advise patients to discontinue use and consult a physician if discomfort persists. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center (1-800-222-1222) should be contacted without delay.

Side Effects

Patients should be aware that the product is for external use only and is flammable; it should be kept away from fire and flames. Application to irritated skin or any areas that are infected or reddened is contraindicated. Additionally, the product should not be used on moles, birthmarks, warts with hair, genital warts, or warts on the face or mucous membranes. It is not recommended for individuals with diabetes or poor blood circulation.

In the event that discomfort persists, patients are advised to stop use and consult a doctor.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there are no known interactions between this medication and laboratory tests. Therefore, no specific dosage adjustments or monitoring recommendations are necessary based on drug interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Ttsiya Wart Remover (wart remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center (1-800-222-1222) should be contacted without delay.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

Pregnant patients should be aware that the safety of this medication during pregnancy has not been established. There are no available data regarding the potential risks or fetal outcomes associated with the use of this medication in pregnant individuals. Healthcare professionals are advised to consider the lack of information when prescribing this medication to women of childbearing potential and to discuss the potential risks and benefits with their patients. It is recommended that healthcare providers remain vigilant and informed about any new data that may emerge regarding the use of this medication in pregnant patients.

Lactation

There is no information available regarding the use of this drug in lactating mothers or any lactation considerations. Consequently, the effects on breastfed infants and the excretion of the drug in human milk remain undetermined. Healthcare professionals should exercise caution and consider the lack of data when advising lactating mothers.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring.

Hepatic Impairment

There is no information available regarding the use of this medication in patients with hepatic impairment. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions specified for individuals with compromised liver function. Healthcare professionals should exercise clinical judgment when considering the use of this medication in patients with liver problems, as the absence of data may necessitate careful monitoring and assessment of the patient's overall health status.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved and the individual patient's response. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and monitoring vital signs. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and if the ingestion was recent.

Additionally, specific antidotes or treatments may be indicated based on the clinical scenario and the substance involved. Consultation with a poison control center or a medical toxicologist is recommended for guidance on the appropriate management strategies tailored to the individual case.

Overall, vigilance and prompt intervention are critical in managing potential overdosage situations effectively.

Nonclinical Toxicology

No information is available regarding teratogenic or non-teratogenic effects. Additionally, there is no data provided concerning nonclinical toxicology, animal pharmacology, or toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep this product out of reach of children. Instruct patients that if the product is swallowed, they should seek medical help or contact a Poison Control Center immediately at 1-800-222-1222.

Patients should be informed not to apply the product to irritated skin or any areas that are infected or reddened. It is important to avoid use on moles, birthmarks, warts with hair, genital warts, or warts on the face or mucous membranes. Additionally, this product is not recommended for individuals with diabetes or poor blood circulation.

Healthcare providers should counsel patients to stop using the product and consult a doctor if discomfort persists.

When using this product, patients should be cautioned to avoid contact with the eyes. In the event that the product gets into the eye, they should flush it with water for 15 minutes. Patients should also be advised to avoid inhaling vapors. It is essential to cap the product tightly and store it at room temperature, away from heat.

Storage and Handling

The product is supplied in a tightly capped container and should be stored at room temperature, away from heat sources. It is essential to avoid inhaling vapors during handling. To ensure safety, the product must be kept out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact a Poison Control Center at 1-800-222-1222.

Additional Clinical Information

The product is administered topically, with specific directions for use that include washing the affected area, soaking the wart in warm water for five minutes, and thoroughly drying the area. Clinicians should instruct patients to apply one drop at a time from the tube to sufficiently cover each wart, allowing it to dry. This procedure may be repeated once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks.

Patients should be counseled to avoid contact with the eyes; in the event of contact, they should flush the eye with water for 15 minutes. Additionally, patients should avoid inhaling vapors, ensure the cap is tightly secured, and store the product at room temperature away from heat.

Drug Information (PDF)

This file contains official product information for Ttsiya Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)